Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
6-hydroxydopamine (6-OHDA)
Parkinson’s disease
Striatal lesion
Tonic dopamine
norbinaltorphimine (nor-BNI)
κ-opioid receptor (KOR)
Journal
Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503
Informations de publication
Date de publication:
15 12 2023
15 12 2023
Historique:
received:
03
08
2023
revised:
21
09
2023
accepted:
29
09
2023
medline:
6
11
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
ppublish
Résumé
Levels of the opioid peptide dynorphin, an endogenous ligand selective for kappa-opioid receptors (KORs), its mRNA and pro-peptide precursors are differentially dysregulated in Parkinson's disease (PD) and following the development of l-DOPA-induced dyskinesia (LID). It remains unclear whether these alterations contribute to the pathophysiological mechanisms underlying PD motor impairment and the subsequent development of LID, or whether they are part of compensatory mechanisms. We sought to investigate nor-BNI, a KOR antagonist, 1) in the dopamine (DA)-depleted PD state, 2) during the development phase of LID, and 3) via measuring of tonic levels of striatal DA. While nor-BNI (3 mg/kg; s.c.) did not lead to functional restoration in the DA-depleted state, it affected the dose-dependent development of abnormal voluntary movements (AIMs) in response to escalating doses of l-DOPA in a rat PD model with a moderate striatal 6-hydroxdopamine (6-OHDA) lesion. We tested five escalating doses of l-DOPA (6, 12, 24, 48, 72 mg/kg; i.p.), and nor-BNI significantly increased the development of AIMs at the 12 and 24 mg/kg l-DOPA doses. However, after reaching the 72 mg/kg l-DOPA, AIMs were not significantly different between control and nor-BNI groups. In summary, while blocking KORs significantly increased the rate of development of LID induced by chronic, escalating doses of l-DOPA in a moderate-lesioned rat PD model, it did not contribute further once the overall severity of LID was established. While we observed an increase of tonic DA levels in the moderately lesioned dorsolateral striatum, there was no tonic DA change following administration of nor-BNI.
Identifiants
pubmed: 37783263
pii: S0006-8993(23)00384-0
doi: 10.1016/j.brainres.2023.148613
pii:
doi:
Substances chimiques
Levodopa
46627O600J
Dopamine
VTD58H1Z2X
Receptors, Opioid, kappa
0
Oxidopamine
8HW4YBZ748
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
148613Subventions
Organisme : NHLBI NIH HHS
ID : T35 HL007479
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008804
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.